PHARMATHENE'S PENTAGON DEALSPHARMATHENE'S PENTAGON DEALSThe threat of bioterrorism hasn't gone away, and the Defense Dept. continues to bolster its biodefense arsenal. This focuses attention on PharmAthene (PIP), which has been awarded defense contracts to make second-generation anthrax vaccines and therapeutic agents against poison nerve gas nerve gas, any of several poison gases intended for military use, e.g., tabun, sarin, soman, and VX. Nerve gases were first developed by Germany during World War II but were not used at that time. . Stephen Brozak of WBB wBB WoltLab Burning Board WBB Wireless BroadBand WBB Will Be Back WBB Stebbins, Alaska (Airport Code) WBB Winnipeg Blue Bombers WBB Waschbrettbauch (German: wash board belly) Securities says Pharm-Athene is a "biodefense pure play," whose shares have dropped to 1.50, down from 2.35 on Sept. 15. Brozak rates it a buy and sees the stock at 5 in a year. (Its big rival, Emergent BioSolutions Emergent BioSolutions (NYSE:EBS) is a multinational biopharmaceutical company headquartered in Rockville, Maryland. The CEO of Emergent BioSolutions is Fuad El-Hibri. The company traces its roots back to 1998 with the acquisition of the vaccine-manufacturing assets of the former , which has been awarded a $448 million contract to supply anthrax vaccines to the Strategic National Stockpile The Strategic National Stockpile (SNS) of the U.S. Centers for Disease Control is a national repository of antibiotics, chemical antidotes, antitoxins, life-support medications, IV administration, airway maintenance supplies, and medical/surgical items. , is trading at 22). As of Nov. 30, "all contracts awarded to us are potentially worth $554 million," says CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. David Wright. Elemer Piros of Rodman & Renshaw rates the stock outperform, with a price target of 6. Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them. Inside Wall Street is posted at businessweek.com/investor at 5 p.m. EST on Thursdays. 
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion